Health Catalyst (HCAT) to Release Earnings on Thursday

Health Catalyst (NASDAQ:HCAT) is anticipated to issue its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $80.59 million for the quarter.

Health Catalyst Stock Performance

Shares of NASDAQ HCAT opened at $3.68 on Thursday. The stock has a market cap of $256.13 million, a PE ratio of -3.20 and a beta of 1.51. Health Catalyst has a 1 year low of $3.49 and a 1 year high of $9.24. The firm has a fifty day moving average price of $3.86 and a 200-day moving average price of $4.37. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.24 and a quick ratio of 1.24.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its stake in Health Catalyst by 816.8% during the first quarter. AQR Capital Management LLC now owns 168,344 shares of the company’s stock worth $763,000 after buying an additional 149,981 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Health Catalyst by 7.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock worth $163,000 after acquiring an additional 2,624 shares during the last quarter. Finally, Focus Partners Wealth bought a new stake in shares of Health Catalyst in the 1st quarter worth about $46,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Citigroup cut their price target on Health Catalyst from $7.00 to $6.50 and set a “buy” rating for the company in a research note on Friday, April 25th. Canaccord Genuity Group cut their target price on Health Catalyst from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Evercore ISI lowered their price target on Health Catalyst from $5.00 to $4.00 and set an “in-line” rating on the stock in a report on Wednesday, July 9th. Stifel Nicolaus increased their price objective on shares of Health Catalyst from $5.00 to $5.50 and gave the company a “hold” rating in a report on Thursday, May 8th. Finally, KeyCorp lowered their target price on shares of Health Catalyst from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, April 16th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.00.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.